UNLABELLED: The aim of the study was to assess whether (11)C-choline PET/CT could identify high-risk primary adenocarcinoma of the prostate. METHODS: (11)C-choline PET/CT and transpelvic MRI were performed in 14 patients with untreated localized primary adenocarcinoma of the prostate, followed by radical prostatectomy as a form of primary monotherapy within 14 d of in vivo imaging. To allow accurate coregistration of whole-mount histology with in vivo imaging, additional ex vivo MR images of the prostatectomy specimen were obtained. Nonlinear 3-dimensional image deformations were used for registrations of PET/CT, MRI, and histology. Volumes of interest from tumor and benign tissue were defined on the basis of histology and were transferred into coregistered (11)C-choline PET/CT volumes to calculate the mean (T((mean))/B) and maximum (T((max))/B) ratio of tumor to benign prostate background. On the basis of MIB-1/Ki-67 expression in tumor tissues represented on a tissue microarray, we assessed whether (11)C-choline uptake correlated with local Gleason score and tumor proliferation. RESULTS: Histology confirmed 42 tumor nodules with Gleason scores between 3 + 2 and 4 + 4, with volumes ranging from 0.03 to 12.6 cm(3). T((mean))/B (P < 0.01) and T((max))/B (P < 0.001) ratios were significantly increased in high-Gleason score (>or=4 + 3) lesions versus 3 + 4 and lower disease but failed to distinguish between 3 + 4 disease versus 3 + 3 and lower. T((mean))/B and T((max))/B ratios were significantly increased in tumors with an MIB-1/Ki-67 labeling index greater than or equal to 5% (P < 0.01). CONCLUSION: On the basis of our preliminary data using ratios of tumor to benign prostate background, (11)C-choline preferentially identified aggressive primary prostate cancer.
UNLABELLED: The aim of the study was to assess whether (11)C-choline PET/CT could identify high-risk primary adenocarcinoma of the prostate. METHODS: (11)C-choline PET/CT and transpelvic MRI were performed in 14 patients with untreated localized primary adenocarcinoma of the prostate, followed by radical prostatectomy as a form of primary monotherapy within 14 d of in vivo imaging. To allow accurate coregistration of whole-mount histology with in vivo imaging, additional ex vivo MR images of the prostatectomy specimen were obtained. Nonlinear 3-dimensional image deformations were used for registrations of PET/CT, MRI, and histology. Volumes of interest from tumor and benign tissue were defined on the basis of histology and were transferred into coregistered (11)C-choline PET/CT volumes to calculate the mean (T((mean))/B) and maximum (T((max))/B) ratio of tumor to benign prostate background. On the basis of MIB-1/Ki-67 expression in tumor tissues represented on a tissue microarray, we assessed whether (11)C-choline uptake correlated with local Gleason score and tumor proliferation. RESULTS: Histology confirmed 42 tumor nodules with Gleason scores between 3 + 2 and 4 + 4, with volumes ranging from 0.03 to 12.6 cm(3). T((mean))/B (P < 0.01) and T((max))/B (P < 0.001) ratios were significantly increased in high-Gleason score (>or=4 + 3) lesions versus 3 + 4 and lower disease but failed to distinguish between 3 + 4 disease versus 3 + 3 and lower. T((mean))/B and T((max))/B ratios were significantly increased in tumors with an MIB-1/Ki-67 labeling index greater than or equal to 5% (P < 0.01). CONCLUSION: On the basis of our preliminary data using ratios of tumor to benign prostate background, (11)C-choline preferentially identified aggressive primary prostate cancer.
Authors: John A D Aston; Vincent J Cunningham; Marie-Claude Asselin; Alexander Hammers; Alan C Evans; Roger N Gunn Journal: J Cereb Blood Flow Metab Date: 2002-08 Impact factor: 6.200
Authors: Sari Laitinen; Paula M Martikainen; Teemu Tolonen; Jorma Isola; Teuvo L J Tammela; Tapio Visakorpi Journal: Int J Cancer Date: 2008-02-01 Impact factor: 7.396
Authors: C R Meyer; J L Boes; B Kim; P H Bland; K R Zasadny; P V Kison; K Koral; K A Frey; R L Wahl Journal: Med Image Anal Date: 1997-04 Impact factor: 8.545
Authors: Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-22 Impact factor: 9.236
Authors: Frédéric Pouliot; Breanne D W Karanikolas; Mai Johnson; Makoto Sato; Saul J Priceman; David Stout; Joanne Sohn; Nagichettiar Satyamurthy; Jean B deKernion; Lily Wu Journal: J Nucl Med Date: 2011-04-15 Impact factor: 10.057
Authors: Michael Souvatzoglou; Matthias Eiber; Toshiki Takei; Sebastian Fürst; Tobias Maurer; Florian Gaertner; Hans Geinitz; Alexander Drzezga; Sibylle Ziegler; Stephan G Nekolla; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer Journal: Eur J Nucl Med Mol Imaging Date: 2013-07-02 Impact factor: 9.236
Authors: John Kurhanewicz; Daniel B Vigneron; Kevin Brindle; Eduard Y Chekmenev; Arnaud Comment; Charles H Cunningham; Ralph J Deberardinis; Gary G Green; Martin O Leach; Sunder S Rajan; Rahim R Rizi; Brian D Ross; Warren S Warren; Craig R Malloy Journal: Neoplasia Date: 2011-02 Impact factor: 5.715
Authors: Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause Journal: Eur J Nucl Med Mol Imaging Date: 2013-02-07 Impact factor: 9.236